July 11, meeting of the Transparency Council.
AOTMiT: Transparency Council, incl. about medications for AD, psoriasis and juvenile idiopathic arthritis
Published June 30, 2022 12:11
Źródło: AOTMiT
The agenda is:
Preparation of a position on the legitimacy of granting consent for the reimbursement of the medicinal product Livmarli (maralixibat) in the indication: skin pruritus in the course of Alagille syndrome.
Preparation of opinions on draft health policy programs of local government units:
"Prevention of overweight and obesity in children of the 3rd grade of primary schools in the City of Kołobrzeg for the years 2022/2024",
"Comprehensive rehabilitation and therapy for disabled children from the Mszana commune",
"Program for the prevention and correction of posture defects in school-age children» Healthy Spine «" (Miedźna Commune).
Preparation of an opinion on reimbursement of drugs containing active substances:
ceterizinum in the indications: atopic dermatitis; food allergy - in patients from 6 months of age; anaphylactic reaction manifested by urticaria or Quincke's angioedema - in patients from 6 months of age,
levocetirizini dihydrochloridum in the indications: atopic dermatitis; food allergy - in patients from 6 months of age; anaphylactic reaction manifested by urticaria or Quincke's angioedema - in patients from 6 months of age,
loratadinum in the indications: atopic dermatitis - in patients from 2 years of age; food allergy - in patients from 2 years of age; anaphylactic reaction manifested by Quincke's urticaria or angioedema - in patients from 2 years of age,
acidum folicum in the indication: psoriasis - in patients treated with methotrexate,
leflunomide in the indication Juvenile idiopathic arthritis - polyarticular form after treatment failure or in the case of methotrexate intolerance.
Source: AOTMiT
